CHO cell / Zhongyi Anke Biotech - LARVOL DELTA

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults. (PubMed, Emerg Microbes Infect) - "Further assays of single point mutations showed that K444T, L452R, N460K, or F486V was key mutations to cause immune evasion. Together, these data suggest that SCOK-Omicron can be used as a booster vaccine candidate in adults receiving subunit protein or inactivated vaccine in response to the epidemic of COVID-19 Omicron subvariants, and the mutation K444T, L452R, N460K, or F486V needs to be considered in future vaccine design."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults. (PubMed, Clin Transl Med) - "Additionally, the incidence of adverse reactions decreased significantly in phase 2 clinical trial. The vaccine SCoK was well tolerated and immunogenic."

Clinical • Journal • P1 data • P1 data • P2 data • P2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell) (clinicaltrials.gov) - P1 | N=216 | Recruiting | Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Trial completion date: Jan 2022 ➔ Jul 2022

Trial completion date • Infectious Disease • Novel Coronavirus Disease

Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells) (clinicaltrials.gov) - P2 | N=480 | Recruiting | Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Trial primary completion date: Jul 2021 ➔ Jul 2022

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell) (clinicaltrials.gov) - P1; N=216; Recruiting; Sponsor: Jiangsu Province Centers for Disease Control and Prevention; Trial primary completion date: Apr 2021 ➔ Dec 2021

Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells) (clinicaltrials.gov) - P2; N=480; Recruiting; Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease

Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell) (clinicaltrials.gov) - P1; N=216; Recruiting; Sponsor: Jiangsu Province Centers for Disease Control and Prevention; Trial primary completion date: Dec 2020 ➔ Apr 2021

Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (CHO Cell) (clinicaltrials.gov) - P1; N=216; Recruiting; Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases